Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

Fischer (all doses)
RCTmolnupiravirplaceboCOVID 19 outpatientssome concern
140/62 suggested
  • suggested 13.5-fold increase in viral clearance ,viral clearance by day 7 with a moderate degree of certainty due to some concern in risk of bias
RCTmolnupiravirplaceboCOVID 19 outpatientslow
716/717 conclusif
  • demonstrated 52 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 51 % decrease in hospitalization with a high degree of certainty due to low risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).